MX2021004207A - Uso de reboxetina para el tratamiento de narcolepsia. - Google Patents

Uso de reboxetina para el tratamiento de narcolepsia.

Info

Publication number
MX2021004207A
MX2021004207A MX2021004207A MX2021004207A MX2021004207A MX 2021004207 A MX2021004207 A MX 2021004207A MX 2021004207 A MX2021004207 A MX 2021004207A MX 2021004207 A MX2021004207 A MX 2021004207A MX 2021004207 A MX2021004207 A MX 2021004207A
Authority
MX
Mexico
Prior art keywords
reboxetine
narcolepsy
cataplexy
treat narcolepsy
treat
Prior art date
Application number
MX2021004207A
Other languages
English (en)
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2021004207A publication Critical patent/MX2021004207A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021004207A 2018-10-15 2019-10-14 Uso de reboxetina para el tratamiento de narcolepsia. MX2021004207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
MX2021004207A true MX2021004207A (es) 2021-08-11

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004207A MX2021004207A (es) 2018-10-15 2019-10-14 Uso de reboxetina para el tratamiento de narcolepsia.

Country Status (16)

Country Link
EP (1) EP3866768A4 (ja)
JP (1) JP2022504975A (ja)
KR (1) KR20210071046A (ja)
CN (1) CN112888430A (ja)
AU (2) AU2019361915A1 (ja)
BR (1) BR112021007019A2 (ja)
CA (1) CA3115983A1 (ja)
CL (1) CL2021000924A1 (ja)
CO (1) CO2021004681A2 (ja)
CR (1) CR20210514A (ja)
EC (1) ECSP21031200A (ja)
IL (1) IL282311A (ja)
MX (1) MX2021004207A (ja)
PE (1) PE20211199A1 (ja)
SG (1) SG11202103588WA (ja)
WO (1) WO2020081461A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (ko) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
KR20070029740A (ko) * 2004-06-09 2007-03-14 화이자 인코포레이티드 통증 치료를 위한 레복세틴의 용도
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi

Also Published As

Publication number Publication date
CR20210514A (es) 2021-11-12
EP3866768A4 (en) 2022-01-05
EP3866768A1 (en) 2021-08-25
CA3115983A1 (en) 2020-04-23
CN112888430A (zh) 2021-06-01
AU2023200917A1 (en) 2023-03-23
CO2021004681A2 (es) 2021-06-21
CL2021000924A1 (es) 2021-09-03
IL282311A (en) 2021-05-31
ECSP21031200A (es) 2021-05-31
PE20211199A1 (es) 2021-07-01
AU2019361915A1 (en) 2021-05-13
WO2020081461A1 (en) 2020-04-23
SG11202103588WA (en) 2021-05-28
JP2022504975A (ja) 2022-01-13
KR20210071046A (ko) 2021-06-15
BR112021007019A2 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX2020001727A (es) Terapia de combinacion.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021002322A (es) Nuevos metodos.
PH12017500392A1 (en) Medical treatments based on anamorelin
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2022006630A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso.
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
EA202190294A1 (ru) Комбинированная терапия для лечения рака
AR122344A1 (es) Uso de reboxetina para tratar desórdenes del sistema nervioso